Migräne-Kranit (Phenazone)

Phenazone inhibits cyclooxygenase enzymes COX‑1 and COX‑2, reducing the production of prostaglandins that mediate inflammation, pain and fever. Lower prostaglandin levels diminish peripheral sensitisation and central perception of pain.

The appropriate dose is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, weight and concomitant therapies. Patients should follow the prescriber’s instructions and the product label.

Safety data for phenazone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

Enquiries can be submitted via the product page on gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Phenazone belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to non‑steroidal anti‑inflammatory drugs (NSAIDs) but with a distinct chemical structure. Compared with paracetamol, phenazone has a stronger anti‑inflammatory component, while its safety profile differs, especially regarding blood‑related adverse events.

Store the product at ambient temperature, preferably below 25 °C, in the original packaging to protect it from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date.

Migräne‑Kranit is intended for oral administration. The tablet should be swallowed whole with a glass of water, unless otherwise directed by a healthcare professional.

Serious adverse reactions include severe allergic responses such as anaphylaxis, blood disorders like agranulocytosis or aplastic anemia, and liver toxicity presenting as jaundice. Immediate medical attention is required if any of these symptoms occur.

Individuals with known hypersensitivity to phenazone or other pyrazolones, those with a history of severe allergic reactions to NSAIDs, and patients with active gastrointestinal ulceration or severe hepatic or renal impairment should avoid using this medication.